Originally published as JCO Early Release 10.1200/JCO.2007.14.5367 on February 19 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chanan-Khan, A. A. Articles by Cheson, B. D. Search for Related Content PubMed PubMed Citation Articles by Chanan-Khan, A. A. Articles by Cheson, B. D. Social Bookmarking                            What's this?

Lenalidomide for the Treatment of B-Cell Malignancies

Asher A. Chanan-Khan, Bruce D. Cheson

From the Roswell Park Cancer Institute, Buffalo, NY; and Georgetown University Hospital, Washington, DC

Corresponding author: Asher A. Chanan-Khan, MD, Elm & Carlton St, Buffalo, NY 14263; e-mail: asher.chanan-khan{at}roswellpark.org

Lenalidomide is a novel anticancer agent that has made a major impact in the treatment of patients with B-cell malignancies. A more potent analog of thalidomide, lenalidomide was developed to enhance immunomodulatory properties with improved safety profile. Its antitumor activity seems mediated through modulation of both the cytokine and cellular tumor cell microenvironment. Preclinical as well as clinical observations demonstrate that lenalidomide downregulates production of various critical prosurvival cytokines in the tumor microenvironment while concurrently promoting activation of T- and natural killer (NK) cell-mediated antitumor response. Early clinical investigations noted its efficacy in relapsed and/or refractory multiple myeloma patients. Subsequently, larger randomized studies confirmed the clinical benefit of lenalidomide when added to dexamethasone compared with dexamethasone alone in previously treated myeloma patients resulting in its recent approval by the US Food and Drug Administration. Consequently, the role of lenalidomide in other B-cell malignancies has been investigated, with impressive results in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. This review summarizes the data from various clinical investigations and highlights the impact of lenalidomide in the management of patients with B-cell malignancies.

published online ahead of print at www.jco.org on February 19, 2008.

Supported in part by the Jerra Barit Myeloma Research Fund (A.C.-K.).

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. L. Dahut, J. B. Aragon-Ching, S. Woo, T. M. Tohnya, J. L. Gulley, P. M. Arlen, J. J. Wright, J. Ventiz, and W. D. Figg Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer J. Clin. Pharmacol., June 1, 2009; 49(6): 650 - 660. [Abstract] [Full Text] [PDF]

				A. Delmonte, M. Ghielmini, and C. Sessa Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas Oncologist, May 1, 2009; 14(5): 511 - 525. [Abstract] [Full Text] [PDF]

				P. Morel, A. Duhamel, P. Gobbi, M. A. Dimopoulos, M. V. Dhodapkar, J. McCoy, J. Crowley, E. M. Ocio, R. Garcia-Sanz, S. P. Treon, et al. International prognostic scoring system for Waldenstrom macroglobulinemia Blood, April 30, 2009; 113(18): 4163 - 4170. [Abstract] [Full Text] [PDF]

				L. Maggio-Price, P. Treuting, H. Bielefeldt-Ohmann, A. Seamons, R. Drivdahl, W. Zeng, L. Lai, M. Huycke, S. Phelps, T. Brabb, et al. Bacterial Infection of Smad3/Rag2 Double-Null Mice with Transforming Growth Factor-{beta} Dysregulation as a Model for Studying Inflammation-Associated Colon Cancer Am. J. Pathol., January 1, 2009; 174(1): 317 - 329. [Abstract] [Full Text] [PDF]